ImetelChat

We can rule out retail and swing trading. Probably not a significant investor but it could be. It could be the ATM, but what would be the justification? I don't think it is bad news since the KOL meeting went off without a hitch today. You're correct to point out the increase in the short position b...

Newswise — Amer Zeidan, MBBS, medical director of the hematology early therapeutics research program at Yale Cancer Center and associate professor of medicine (hematology) at Yale School of Medicine, will reveal new data at the American Society of Clinical Oncology (ASCO) annual meeting from a phase...

May 25, 2023 Asco 2023 – Commands leaves the door open for Geron author Jacob Plieth Full data from Reblozyl’s Commands study show limited activity in MDS patients without ringed sideroblasts – a boon for Geron. The recently intensifying battle in myelodysplastic syndromes between Bristol Myers Squi...

I'm on board as well BP. JS is either a better con man than our former president or has very strong feelings about Imetelstat's prospects. I didn't sign on over twenty years ago to settle. My only caveat is that they should continue the pr approach they've taken over the last month, i.e. stay on the...

I think the timing of the Times article may be propitious. As a layman, it seems to support Scarlett's statement that Imetelstat alters the disease progression for MDS and probably MF. I think it will be an easier proposition to sell going forward and lays the foundation for Imetelstat to become a s...

Geron needs a 3-5 Billion $ market cap before any additional shares are sold, i.e. the next secondary needs to be above $6 then the funding from 100m shares should put the company over the top in terms of financing and would probably not cause the pps to suffer. Revenues will begin in 2024 and hopef...

Agreed HB - One of his best conference calls/chats. I especially enjoyed the heavy emphasis he placed on creating shareholder value. He also conveyed clearly that the only significant potential side effect was cytopenias which he stated were resolved quickly. Overall it was good to get confirmation ...

Ryan, Scarlett is the CEO and the stock has responded miserably to what should have been excellent news - why do you think that is the case?

Ryan - I still have faith in the ultimate success of Imetelstat and do not plan to sell any of my shares in this price range. I do believe that Scarlett is potentially taking the appropriate action needed to protect against a hostile takeover. OTH, he has not shown any capability of managing the pps...

After reading the Proxy Statement it is clear that Geron anticipates raising capital through stock sales at every opportunity - which is both nauseating and understandable. They will not have any significant revenue until late 2024 at the earliest. They have also failed in their 'Stretch Goal' of in...

From TalksOnLaw A “poison pill” is a defensive tactic used to discourage a hostile takeover. Professor John D. Morley of Yale Law School explains (1) how they work, (2) why they are so effective at stopping hostile acquisitions, and (3) how can they be overcome. A poison pill is a tool used by corpo...

From Digital Report Myelofibrosis Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Imago Biosciences, Actuate, Galecto, NS Pharma, Geron, iOnctura, Incyte Corporation, Keros Therapeutics, elgene/BMS, Sierra Oncology, AbbVie, Kartos T...

Anyone who has followed this stock for more than a few days would quickly come to the conclusion that the pps is being manipulated and that the Yahoo board is flooded with paid bashers. I think Seeking Alpha has also been compromised by folks who are committed to minimally destroying confidence in S...

Great post HI - Hopefully you're on target and Geron has plans to exploit the potential.

Does anyone have a fair idea of the value, (i.e. broadness and specificity) of Geron's patents? I'm curious about the impact of Geron's patents on a potential BO calculation. I've just done a cursory review of alternate methods of Telomerase Inhibition as well as Activation and it seems as though th...

HI - I think your numbers are in the ballpark. Short-short-term we will not get 7-10b. I think we need FDA approval for 7-10b.

Anyone who has followed this stock for a significant period of time would have had to recognize SP manipulation that could only be explained by pervasive, unlimited Naked Shorting. In all probability, Geron shareholders have been victimized similarly to the GNS shareholders. I will absolutely suppor...

Well said BP - we Geronites are adept at adjusting our time horizons. Although I had picked out a new boat, I'll have to settle for a night out at Taco Bell. I do share your confidence and look forward to a long continuum of good fortune thanks to the success of this drug.

We're all familiar with the cliche - "No pain, no gain". In this case, believing that the gain will justify this pain is getting harder. Scarlett needs to explain why he needed $175,000,000 when he had over $100 million still available. Perhaps this stock offering is the reason our high-priced IR ex...

HI - I share your sentiments - well spoken - thanks for sharing.